These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 32334548)

  • 1. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
    Kim S; Buecher B; André T; Jary M; Bidard FC; Ghiringhelli F; François É; Taieb J; Smith D; de la Fouchardière C; Desramé J; Samalin E; Parzy A; Baba-Hamed N; Bouché O; Tougeron D; Dahan L; El Hajbi F; Jacquin M; Rebucci-Peixoto M; Spehner L; Vendrely V; Vernerey D; Borg C
    BMC Cancer; 2020 Apr; 20(1):352. PubMed ID: 32334548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
    Kim S; Jary M; André T; Vendrely V; Buecher B; François E; Bidard FC; Dumont S; Samalin E; Peiffert D; Pernot S; Baba-Hamed N; El Hajbi F; Bouché O; Desrame J; Parzy A; Zoubir M; Louvet C; Bachet JB; Nguyen T; Abdelghani MB; Smith D; De La Fouchardière C; Aparicio T; Bennouna J; Gornet JM; Jacquin M; Bonnetain F; Borg C
    BMC Cancer; 2017 Aug; 17(1):574. PubMed ID: 28841909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
    Kim S; Ghiringhelli F; de la Fouchardière C; Evesque L; Smith D; Badet N; Samalin E; Lopez-Trabada Ataz D; Parzy A; Desramé J; Baba Hamed N; Buecher B; Tougeron D; Bouché O; Dahan L; Chibaudel B; El Hajbi F; Mineur L; Dubreuil O; Ben Abdelghani M; Pecout S; Bibeau F; Herfs M; Garcia ML; Meurisse A; Vernerey D; Taïeb J; Borg C
    Lancet Oncol; 2024 Apr; 25(4):518-528. PubMed ID: 38547895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
    Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
    Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
    Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
    BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
    Wang J; Xu R; Li J; Bai Y; Liu T; Jiao S; Dai G; Xu J; Liu Y; Fan N; Shu Y; Ba Y; Ma D; Qin S; Zheng L; Chen W; Shen L
    Gastric Cancer; 2016 Jan; 19(1):234-44. PubMed ID: 25604851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma.
    Kim S; Boustani J; Vernerey D; Vendrely V; Evesque L; Francois E; Quero L; Ghiringhelli F; de la Fouchardière C; Dahan L; Bouché O; Chibaudel B; Hajbi FE; Vernet C; Rebucci-Peixoto M; Feuersinger A; Maritaz C; Borg C
    Front Oncol; 2022; 12():918499. PubMed ID: 36119522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
    Inal A; Kaplan MA; Kucukoner M; Isikdogan A
    Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.
    Kim S; Jary M; Mansi L; Benzidane B; Cazorla A; Demarchi M; Nguyen T; Kaliski A; Delabrousse E; Bonnetain F; Letondal P; Bosset JF; Valmary-Degano S; Borg C
    Ann Oncol; 2013 Dec; 24(12):3045-50. PubMed ID: 24114858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.
    Demirci NS; Aksoy S; Özdemir NY; Erdem GU; Ozcelik M; Tanrikulu E; Eren T; Bozkaya Y; Sahin S; Başol F; Aslan SA; Zengin N; Güllü İ
    Curr Med Res Opin; 2017 Mar; 33(3):401-407. PubMed ID: 27817239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma.
    Kim S; Meurisse A; Spehner L; Stouvenot M; François E; Buecher B; André T; Samalin E; Jary M; Nguyen T; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; de la Fouchardiere C; Boulbair F; Lakkis Z; Klajer E; Jacquin M; Taieb J; Vendrely V; Vernerey D; Borg C
    Ther Adv Med Oncol; 2020; 12():1758835920975356. PubMed ID: 33329760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
    Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
    J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
    Grau JF; Farinas-Madrid L; Oaknin A
    Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Telomerase CD4
    Spehner L; Kim S; Vienot A; François E; Buecher B; Adotevi O; Vernerey D; Abdeljaoued S; Meurisse A; Borg C
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
    Stouvenot M; Meurisse A; Saint A; Buecher B; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Smith D; Ghiringhelli F; Parzy A; de la Fouchardiere C; Almotlak H; Vienot A; Jacquin M; Taieb J; Nguyen T; Vernerey D; Borg C; Kim S
    Eur J Cancer; 2022 Feb; 162():138-147. PubMed ID: 34995900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
    Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
    Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer.
    Mondaca S; Chatila WK; Bates D; Hechtman JF; Cercek A; Segal NH; Stadler ZK; Varghese AM; Kundra R; Capanu M; Shia J; Schultz N; Saltz L; Yaeger R
    Clin Colorectal Cancer; 2019 Mar; 18(1):e39-e52. PubMed ID: 30316684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Squamous cell anal carcinoma. What's next ?].
    Kim S; Spehner L; Cabel L; Bidard FC; Borg C
    Bull Cancer; 2021 Jan; 108(1):80-89. PubMed ID: 33423780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.
    Morris VK; Salem ME; Nimeiri H; Iqbal S; Singh P; Ciombor K; Polite B; Deming D; Chan E; Wade JL; Xiao L; Bekaii-Saab T; Vence L; Blando J; Mahvash A; Foo WC; Ohaji C; Pasia M; Bland G; Ohinata A; Rogers J; Mehdizadeh A; Banks K; Lanman R; Wolff RA; Streicher H; Allison J; Sharma P; Eng C
    Lancet Oncol; 2017 Apr; 18(4):446-453. PubMed ID: 28223062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.